| Literature DB >> 34305771 |
Soumia Benbrika1, Franck Doidy1, Laurence Carluer1, Audrey Mondou1, Alice Pélerin1, Francis Eustache1, Fausto Viader1, Béatrice Desgranges1.
Abstract
Objectives: Extra-motor manifestations occur in 50% of patients with amyotrophic lateral sclerosis (ALS). These mainly concern cognition, emotional processing and behavior. Depression and anxiety are less frequent. Little is known about how these manifestations change as the disease progresses. Similarly, although cortical thinning has been well-documented at disease onset, there are scant data about cortical thinning over time and how this correlates with extra-motor manifestations. The present study therefore assessed cognitive, emotional and psychological state and cortical thinning in a group of patients with ALS at baseline and after a follow-up period.Entities:
Keywords: amyotrophic lateral sclerosis; cognition; emotional processing; neural correlate; psychological assessment
Year: 2021 PMID: 34305771 PMCID: PMC8296637 DOI: 10.3389/fneur.2021.620198
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Sociodemographic, clinical, psychological and cognitive data of patients and controls at baseline.
| Sex (male/female) | 25/18 | 17/11 | 0.05 |
| Age (years) | 61 ± 11 | 57.8 ± 8.9 | 0.13 |
| Education level (years) | 9.9 ± 2.9 | 11 ± 2.7 | 0.08 |
| ALSFRS (/48) | 38 ± 5.3 | / | / |
| MRC (/120) | 102 ± 15.3 | / | / |
| Norris scale (/39) | 34.6 ± 6.15 | / | / |
| BDI (/39) ( | 4.8 ± 4.49 | 1.9 ± 2.1 | <0.001 |
| STAI-Y 1 (/80) ( | 34.9 ± 1.9 | 26.5 ± 6.13 | <0.001 |
| STAI-Y 2 (/80) ( | 36.12 ± 10.2 | 34.5 ± 8.26 | 0.57 |
| TMT B-A time (s) ( | 67.9 ± 60.17 | 36.8 ± 31.3 | 0.01 |
| Animal VF Index ( | 3.7 ± 1.0 | 3.2 ± 0.9 | 0.08 |
| Letter VF Index ( | 7.78 ± 5.8 | 4.4 ± 1.22 | <0.001 |
| HSCT ( | 5.3 ± 2.7 | 8.5 ± 3.2 | <0.001 |
| LN sequencing ( | 8.7 ± 3.6 | 10.1 ± 2.64 | 0.07 |
| FET-eyes be ( | 5.95 ± 1.2 | 6.5 ± 1.5 | 0.06 |
| FET-eyes ce ( | 5.02 ± 1.6 | 5.8 ± 2.3 | <0.001 |
| FET-face be ( | 7.06 ± 1.5 | 7.5 ± 1.6 | 0.22 |
| FET-face ce ( | 5.5 ± 1.7 | 7.1 ± 2.3 | <0.001 |
Values are mean ± SD. ALSFRS, ALS Functional Rating Scale; MRC, Medical Research Council Muscle Strength Scale; BDI, Beck Depression Inventory; STAI-Y, Spielberger State and Trait Anxiety Inventory; 1, State; 2, Trait; TMT, Trail Making Test; VF, Verbal Fluency; HSCT, Hayling Sentence Completion Test; LN sequencing, Letter-Number Sequencing task; FET, Face Eyes Test; be, basis emotions; ce, complex emotions. Significance set at p < 0.05.
Comparison of baseline sociodemographic, neurological, cognitive and emotional characteristics between patients included and not included at follow-up.
| Age (years) | 62.5 ± 10.5 | 59.4 ± 11.6 | 0.40 |
| Sex (male/female) | 12/9 | 13/9 | 0.02 |
| Education level (in years) | 9.5 ± 3.0 | 10.3 ± 2.7 | 0.23 |
| ALSFRS | 35.8 ± 5.2 | 40.1 ± 4.6 | <0.01 |
| Norris scale | 34.1 ± 5.8 | 35.1 ± 6.5 | 0.26 |
| MRC | 101.9 ± 13.7 | 102.3 ± 17.1 | 0.65 |
| Spinal vs. Bulbar | 16/6 | 16/5 | 0.07 |
| BDI (/39) | 3.3 ± 2.6 | 6.6 ± 5.6 | 0.06 |
| STAI-Y 1 (/80) | 34.2 ± 10.7 | 35.7 ± 11.7 | 0.64 |
| STAI-Y 2 (/80) | 34.8 ± 9.6 | 37.7 ± 6.1 | 0.56 |
| TMT B-A time (s) | 62.0 ± 58.1 | 74.9 ± 63.6 | 0.90 |
| Animal VF Index | 3.6 ± 1.1 | 3.9 ± 1.0 | 0.13 |
| Letter VF Index | 6.6 ± 2.2 | 9.2 ± 8.3 | 0.23 |
| HSCT | 5.0 ± 2.6 | 5.8 ± 3.0 | 0.40 |
| LN sequencing | 9.0 ± 3.9 | 8.3 ± 3.8 | 0.67 |
| FET-eyes be | 6.0 ± 1.3 | 6.1 ± 1.é | 0.85 |
| FET-eyes ce | 5.0 ± 1.7 | 5.1 ± 1.7 | 0.85 |
| FET-face be | 7.0 ± 1.4 | 6.9 ± 1.9 | 0.87 |
| FET-face ce | 5.4 ± 1.6 | 5.7 ± 1.8 | 0.53 |
Values are mean ± SD. ALSFRS, ALS Functional Rating Scale; MRC, Medical Research Council Muscle Strength Scale; BDI, Beck Depression Inventory; STAI-Y, Spielberger State and Trait Anxiety Inventory; 1, State; 2, Trait; TMT, Trail Making Test; VF, Verbal Fluency; HSCT, Hayling Sentence Completion Test; LN sequencing, Letter-Number Sequencing task; FET, Face Eyes Test; be, basis emotions; ce, complex emotions. MDRS, Mattis Demencia Rating Scale; Significance set at p < 0.05.
Changes in neurological, psychological and cognitive scores of patients with ALS evaluated at baseline and follow-up.
| ALSFRS ( | 40.1 ± 4.6 | 29.7 ± 1.6 | <0.001 |
| Norris scale ( | 35.1 ± 6.5 | 29.1 ± 12.4 | <0.001 |
| MRC ( | 102.3 ± 17.1 | 81.2 ± 28.8 | <0.001 |
| BDI (/39) ( | 3.3 ± 2.6 | 4.0 ± 4.5 | 0.5 |
| STAI-Y 1 (/80) ( | 34.2 ± 10.5 | 31.52 ± 9.7 | 0.1 |
| STAI-Y 2 (/80) ( | 34.8 ± 9.64 | 37.6 ± 11 | 0.4 |
| TMT B-A (s) ( | 62.0 ± 58.1 | 53.75 ± 38.1 | 0.9 |
| Animal VF index ( | 3.6 ± 1.1 | 3.7 ± 1.3 | 0.8 |
| Letter VF index ( | 6.6 ± 2.2 | 6.1 ± 2.0 | 0.7 |
| HSCT ( | 9.7 ± 2.4 | 5.2 ± 2.9 | 0.008 |
| LN-sequencing ( | 9.0 ± 3.9 | 9.6 ± 4.2 | 0.7 |
| FET-eyes be ( | 6.0 ± 1.2 | 6.0 ± 1.8 | 0.9 |
| FET-eyes ce ( | 4.8 ± 1.6 | 5.0 ± 1.8 | 0.7 |
| FET-face be ( | 7.0 ± 1.4 | 6.9 ± 1.8 | 0.9 |
| FET-face ce ( | 5.1 ± 1.6 | 4.9 ± 2.0 | 0.7 |
Values are means ± SD. ALSFRS, ALS Functional Rating Scale; MRC, Medical Research Council Muscle Strength Scale; BDI, Beck Depression Inventory; STAI-Y, Spielberger State and Trait Anxiety Inventory; 1, State; 2, Trait; TMT, Trail Making Test; VF, Verbal Fluency; HSCT, Hayling Sentence Completion Test; LN sequencing, Letter-Number Sequencing task; FET, Face Eyes Test; be, basis emotions; ce, complex emotions. Significance set at p < 0.05.
Changes in cortical thickness in patients at baseline (compared to controls) and at follow-up (compared to baseline).
| • Right and left pre-central and post-central | • Left and right pre-central |
Figure 1Changes in cortical thickness in patients at baseline compared to controls.
Figure 2Correlations at baseline between cortical thickness and TMT B-A and recognition of complex facial emotions.
Figure 3Changes in cortical thickness in patients at follow-up compared to baseline.
Figure 4Correlations between changes of Cortical Thickness and those of abnormal clinical scores: TMT B-A (A), letter-fluency index (B), Beck Depression Inventory (C).